Sprint Bioscience's stock is surging after the company announced an agreement with Gilead Sciences to sell its preclinical cancer program, TREX1. The deal includes an upfront payment of USD 14 million, with the potential for further milestone payments bringing the total deal value up to USD 400 million. BioStock reached out to CEO Johan Emilsson for more information.

Read the full article at biostock.se:
https://biostock.se/en/2025/11/sprint-bioscience-saljer-cancerprogrammet-trex1-till-gilead/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!  

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Läs mer på BioStock